Vivani Medical in Alameda Raises $5.1M After Implant Trial
Two board members are buying the stock days after the first human test of its semaglutide implant.
By The Alameda Pulse

Vivani Medical, a biotech company in the Harbor Bay Business Park in Alameda, CA, said on Nov. 16, 2026 that two of its board members are buying about $5.1 million of its stock. The sale comes days after the first human trial of NPM-139, Vivani's tiny implant that releases semaglutide.
- Where: Vivani Medical headquarters, 1350 S. Loop Road, Alameda
- The deal: 5,049,506 shares at $1.01 each, about $5.1 million before expenses
- Buyers: Board chairman Gregg Williams and board member Aaron Mendelsohn
- Closing: Expected on or about Nov. 23, 2026
- Next: A Phase 2 trial of NPM-139, expected to start in 2027
What is Vivani Medical's NPM-139 implant?
NPM-139 is a miniature implant from Vivani Medical that's built to release semaglutide slowly over a long time. Semaglutide is the drug in Wegovy, a weekly shot for weight loss. Vivani designs its implants for once or twice a year, so people don't have to remember a pill or a shot. The company says about half of patients don't take their medicine as prescribed.
What did the first NPM-139 trial show?
Vivani says none of the 10 people who got NPM-139 in its first human trial had a side effect linked to the treatment. The trial is called SLIM-1. It ran four weeks with 20 healthy adults who were overweight or had obesity. Ten got a low dose of NPM-139. The other 10 got the starting dose of Wegovy, 0.25 mg a week.
Five of the 10 people on Wegovy had side effects linked to the drug, and all of them were stomach problems. Nobody in the trial had a serious side effect. It's a small study, and these are the company's own top-line results, which it announced on Nov. 12, 2026.
Who is buying the $5.1 million in Vivani stock?
Gregg Williams, the chairman of Vivani's board, and Aaron Mendelsohn, another board member, are buying the $5.1 million in Vivani stock. They pay $1.01 a share in a private sale. Vivani says the price is "at-the-market" under Nasdaq rules. The company trades on Nasdaq as VANI.
What happens next?
Vivani expects the sale to close on or about Nov. 23, 2026. The company plans to spend the money on NPM-139, its other products and day-to-day costs. Vivani says the new money and its cash on hand will pay for its work into the third quarter of 2027.
The next step is a Phase 2 trial in 2027. That trial tests different doses of NPM-139 to help people keep weight off. Read the details in Vivani's Nov. 16 press release filed with the SEC, and find more Alameda business news here at the Pulse.
Source: sec.gov (opens in a new tab)

